"Valiumgirl" could use some. There's some kind of agenda here, but it's not worth the time to examine. In terms of some points raised:
1) Stoll has identified fentanyl/opioid RD as the first target. He listed nine additional possibilities. The references to propofol by this rant are a red herring.
2) I think it's probably a safe assumption that they aren't going to induce RD in healthy subjects and then reverse it. Again, a red herring claim. CX717 has been used in a couple hundred humans--enough to do a Phase IIa in patients with real RD. How the UK group does that has not been revealed, but it's pretty funny that VG claims that, since it's not on CenterWatch or ClinTrials, it's not real.
3) Alternative opioid RD antidotes:
Nalbuphine: From a Canadian anesthesia research group: <<However, hypertension, increased heart rate, and significant increase in analogue pain scores accompanied reversal of respiratory depression. Agitation, nausea, vomiting, and cardiac dysrhythmias also were observed frequently.>>
D1 agonists: Cause hypotension--not a good thing to have a BP drop in surgery--or at least, it's better to not have it.
5HT4: GI effects are the desired target for this drug class, and may not be desirable in this population. Also--one 5HT4 agonist caused serious cardiac problems and had to be withdrawn in the US.
None of these has demonstrated itself to be a problem-free option for RD.
Bottom line-VG ignored half of what was said and then pretends that the lack of that information indicts the whole plan. Really smarmy and distorted.
NeuroInvestment
